Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2009-02-26 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a public announcement regarding abnormal stock trading fluctuations for the company 中源协和干细胞生物工程股份公司. It discusses stock price movements, confirms no undisclosed material information, and provides a risk warning to investors. There is no financial data, no report attached or referenced as being published, and no mention of management changes, dividends, or legal proceedings. The content fits the profile of a regulatory announcement about stock trading irregularities rather than a financial report or other specific filing. Therefore, it best fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2009-02-26 Chinese
股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a public announcement regarding abnormal stock price fluctuations for the company 中源协和干细胞生物工程股份公司. It discusses stock price limits being hit over consecutive days, confirms no undisclosed material information or restructuring plans, and provides a risk warning to investors. There is no financial data, no report attached or referenced as being published, and no mention of management changes, dividends, or legal proceedings. The content fits the profile of a regulatory announcement about stock trading abnormalities rather than a financial report or meeting material. Therefore, it best fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2009-02-19 Chinese
股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a public announcement regarding abnormal stock price fluctuations for the company 中源协和干细胞生物工程股份公司. It discusses stock price limits being hit on specific dates, inquiries made to controlling shareholders and management, and confirms no undisclosed material information exists. There is no financial data, no detailed report, no meeting materials, no voting results, no legal proceedings, or other report types. This is a regulatory announcement about stock trading behavior and company disclosures, fitting the category of Regulatory Filings (RNS). The document length is short and it is not a report itself but an announcement. Therefore, the classification is RNS with high confidence.
2009-02-16 Chinese
企业名称及证券简称变更公告
Regulatory Filings Classification · 95% confidence The document is a short announcement regarding the change of the company's name and securities abbreviation, including regulatory approvals and effective dates. It does not contain financial data, management discussion, or detailed report content. It is an official announcement about corporate identity and securities listing information, which fits best under Regulatory Filings (RNS) as it does not match other more specific categories like Annual Report or Capital Update.
2009-02-11 Chinese
第二大股东的股份被司法冻结的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement regarding the judicial freezing of shares held by the company's second largest shareholder. It includes details about the number of shares frozen, the legal case involved, and the freezing period. There is no financial data, no report attached or referenced as being published, and no mention of management changes or voting results. This type of announcement fits best under Regulatory Filings (RNS) as it is a regulatory disclosure about a legal/ownership matter that does not fit other specific categories.
2009-01-22 Chinese
2008年度业绩预增公告
Earnings Release Classification · 95% confidence The document is a performance forecast announcement for the fiscal year 2008, indicating expected net profit growth and stating that detailed data will be disclosed in the 2008 annual report. It explicitly mentions that the forecast has not been audited and is preliminary. The document is short (655 characters) and serves as an earnings preview rather than a full financial report. It does not contain actual financial statements or detailed analysis, only a forecast and cautionary notes. Therefore, it fits the category of an Earnings Release (ER), which is the initial announcement of quarterly or periodical financial results highlighting key figures and expectations. FY 2008
2009-01-22 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.